Xenobiotica | Apr. 2020 Correlation of the in vitro Biotransformation of H3B-6527 in Dog and Human Hepatocytes With the in vivo Metabolic Profile of 14 C-H3B-6527 in a Dog Mass Balance Study 1. H3B-6527 is an orally available covalent small molecule inhibitor of FGFR4 undergoing evaluation in adults with hepatocellular carcinoma. Absorption,… Read More
Cancer Chemotherapy and Pharmacology | Jan. 2019 Effect of a High-Fat Meal on the Relative Bioavailability of H3B-6527, a Novel FGFR4 Inhibitor, in Healthy Volunteers Purpose: This Phase I study estimated the effect of a high-fat meal on the pharmacokinetics (PK) of H3B-6527, a covalent… Read More
Cancer Research | Dec. 15, 2017 H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Activation of the fibroblast growth factor receptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if any,… Read More